Respiratory Medicine
Volume 104, Issue 5 , Pages 668-674 , May 2010

Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: A randomised controlled trial

  • Duncan B. Richards

      Affiliations

    • Drug Discovery, GlaxoSmithKline, Stevenage CB2 2GG, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44 1223 296159.
    • ,
  • Philippe Bareille

      Affiliations

    • Drug Discovery, GlaxoSmithKline, Stevenage CB2 2GG, UK
    • ,
  • Emma L. Lindo

      Affiliations

    • Discovery Biometrics, GlaxoSmithKline, Greenford, UK
    • ,
  • Dean Quinn

      Affiliations

    • P3 Research, Bowen Hospital, Wellington, New Zealand
    • ,
  • Stuart N. Farrow

      Affiliations

    • Drug Discovery, GlaxoSmithKline, Stevenage CB2 2GG, UK

Received 23 July 2009 ,Accepted 10 November 2009.

References 

  1. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem. 1997;272(45):28210–28217
  2. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, et al. Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT 4 as measured by photoaffinity labeling. Diabetes. 1995;44:1087–1092
  3. Benayoun L, Letuve S, Druilhe A, Boczkowski J, Dombret MC, Mechighel P, et al. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am J Respir Crit Care Med. 2001;164(8 Pt 1):1487–1494
  4. Belvisi MG, Hele DJ. Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest. 2008;134(1):152–157
  5. Spears M, Donnelly I, Jolly L, Brannigan M, Ito K, McSharry C, et al. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther. 2009;86(1):49–53
  6. Ward JE, Tan X. Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease. PPAR Res. 2007;2007:14983
  7. Marx N, Kehrle B, Kohlhammer K, Grub M, Koenig W, Hombach V, et al. PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res. 2002;90(6):703–710
  8. Ueki S, Adachi T, Bourdeaux J, Oyamada H, Yamada Y, Hamada K, et al. Expression of PPARgamma in eosinophils and its functional role in survival and chemotaxis. Immunol Lett. 2003;86(2):183–189
  9. Mueller C, Weaver V, Vanden Heuvel JP, August A, Cantorna MT. Peroxisome proliferator-activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma. Arch Biochem Biophys. 2003;418(2):186–196
  10. Woerly G, Honda K, Loyens M, Papin JP, Auwerx J, Staels B, et al. Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation. J Exp Med. 2003;198(3):411–421
  11. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P. PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol. 2003;139(1):163–171
  12. Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care. 2002;25(2):401
  13. Young PW, Buckle DR, Cantello BCC, Chapman H, Clapham JC, Coyle PJ, et al. Identification of high-affinity binding sites for the insulin-sensitizer rosiglitazone (BRL 49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor gamma. J Pharmacol Exp Ther. 1998;284:751–759
  14. Seimandi M, Lemaire G, Pillon A, Perrin A, Carlavan I, Voegel JJ, et al. Differential responses of PPARalpha, PPARdelta, and PPARgamma reporter cell lines to selective PPAR synthetic ligands. Anal Biochem. 2005;344(1):8–15
  15. Silvestri M, Oddera S, Sacco O, Balbo A, Crimi E, Rossi GA. Bronchial and bronchoalveolar inflammation in single early and dual responders after allergen inhalation challenge. Lungs. 1997;175(4):277–285
  16. Grzelewska-Rzymowska I, Gondorowicz K, Cieslewicz G, Rozniecki J. Course of non-specific bronchial reactivity to histamine after bronchospasm induced by allergen challenge in patients with bronchial asthma. Pneumonol Alergol Pol. 1995;63(5–6):273–280
  17. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, et al. ERS Task Force. Indirect airway challenges. Eur Respir J. 2003;21(6):1050–1068
  18. van den Berge M, Kerstjens HA, Meijer RJ, de Reus DM, Koeter GH, Kauffman HF, et al. Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med. 2001;164(7):1127–1132
  19. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89(6):2728–2735
  20. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002;25(2):376–380
  21. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Rosiglitazone Clinical Trials Study Group. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care. 2001;24(2):308–315
  22. Kidney JC, Boulet LP, Hargreave FE, et al. Evaluation of single-dose inhaled corticosteroid activity with an allergen challenge model. J Allergy Clin Immunol. 1997;100:65–70
  23. Palmqvist M, Bruce C, Sjostrand M, Arvidsson P, Lotvall J. Differential effects of fluticasone and montelukast on allergen-induced asthma. Allergy. 2005;60:65–70
  24. Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S, et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med. 2007;176(10):988–993
  25. Alving K, Weitzberg E, Lundberg JM. Increased amount of nitric oxide in exhaled air of asthmatics. Eur Respir J. 1993;6:1368–1370
  26. Kharitonov SA, Yates D, Robbins RA, et al. Increased nitric oxide in exhaled air of asthmatic patients. Lancet. 1994;343:133–135
  27. Hansel TT, Erin EM, Barnes PJ. The allergen challenge. Clin Exp Allergy. 2002;32(2):162–167
  28. van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ. Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax. 1999 May;54(5):403–408
  29. Crosby MB, Svenson JL, Zhang J, Nicol CJ, Gonzalez FJ, Gilkeson GS. Peroxisome proliferation-activated receptor (PPAR)gamma is not necessary for synthetic PPARgamma agonist inhibition of inducible nitric-oxide synthase and nitric oxide. J Pharmacol Exp Ther. 2005;312(1):69–76
  30. Thomson NC, Shepherd M, Spears M, Chaudhuri R. Corticosteroid insensitivity in smokers with asthma: clinical evidence, mechanisms, and management. Treat Respir Med. 2006;5(6):467–481

PII: S0954-6111(09)00370-9

doi: 10.1016/j.rmed.2009.11.006

Respiratory Medicine
Volume 104, Issue 5 , Pages 668-674 , May 2010

Article Tools

* Image Usage & Resolution